Posted November 07, 2018 07:11:06A new batch of $100 million worth of Twiga’s COVID vaccines has been stockpiled at its facilities in Canada, amid concerns that the coronavirus pandemic is forcing the company to scale back its manufacturing and supply chains.
The company has been under mounting pressure in the U.S. and Europe to deliver its vaccines and has been criticized by pharmaceutical giant Pfizer and the US Centers for Disease Control and Prevention for delaying the shipment of its vaccines to the United States and Canada.
A spokesperson for the company said that it has now completed the process of shipping its vaccines back to Canada and is now “preparing the next batch of vaccine for distribution to patients.”
In response to the increased demand for Twiga vaccines, the company announced last month that it would stop manufacturing the vaccines for the United Kingdom, the European Union and Australia, according to Reuters.
A statement from the company told Reuters that it “had not received a request from the U/V [U.K.] government for vaccine production.”
The company’s announcement came after reports that a group of doctors and researchers were working with Pfizer on developing a vaccine for the pandemic.
Pfizer has said it will not be making a vaccine to combat the coronovirus, but is committed to providing research to help doctors develop vaccines.
Twiga has been one of the world’s leading producers of COVE vaccines since 1999, when it acquired its U.K. subsidiary, GlaxoSmithKline.
The company has produced some 80 million doses of COVP vaccine to date.
Twida, the parent company of Twigan’s vaccine, told Reuters last month the vaccine had been delivered in “a timely manner” to “over 100 countries in the world.”
“We have delivered the vaccines to over 100 countries for a total of over $400 million worth in COVE vaccine deliveries,” the spokesperson said.
“This is a significant milestone for us and is testament to our global team of experts and a huge amount of trust from the entire Twiga team.”
According to the statement, Twiga will now “be providing vaccines for use in developing countries, including those that have seen significant progress in developing COVID and in reducing COVID transmission,” adding that the vaccine will be made available to “other vaccine producers, and will be a part of our global distribution network.”
The spokesman also told Reuters, “We have a strong partnership with the World Health Organization (WHO) and we have made significant progress towards developing a COVE-vaccine for distribution in countries with the most severe COVID infections.
We are also currently working with the U./V to develop an international COVE supply chain.”
Twiga is a unit of the chemical company Twiga Group, which owns several large industrial companies.
The companies are also part of a consortium called the American Chemical Society (ACS).
The Associated Press contributed to this report.